WHO Releases 2026 Guidelines for GLP-1 Therapies in Obesity Management

Executive Brief

News Report

The News: WHO has released new guidelines for GLP-1 therapies in obesity management.
Clinical Win: These guidelines emphasize a comprehensive approach to obesity treatment.
Target Specialty: Endocrinology

Key Data at a Glance

Guideline Release Date: December 1, 2025
Target Population: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbid conditions
Recommended Therapies: GLP-1 receptor agonists and GLP-1/GIP dual agonists

The World Health Organization (WHO) has released its first global guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for treating obesity, emphasizing the need for a comprehensive approach to manage this chronic disease. Announced on December 1, 2025, the guidelines aim to address the growing obesity epidemic, which affects over one billion people worldwide and is linked to millions of preventable deaths each year.

Clinical Context

Obesity is a complex, chronic disease that significantly increases the risk of developing various noncommunicable diseases, including cardiovascular diseases, type 2 diabetes, and certain cancers. The WHO has recognized obesity as a major global health challenge, necessitating effective management strategies. Current treatment options include lifestyle modifications, pharmacotherapy, and surgical interventions. However, many patients struggle to achieve and maintain significant weight loss through lifestyle changes alone. GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown efficacy in promoting weight loss and improving metabolic health. The recent WHO guidelines underscore the importance of integrating these medications into a broader treatment framework that includes behavioral support and long-term follow-up.

Key Findings

The WHO guidelines recommend the use of GLP-1 therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition [1].

These therapies should be used as part of a comprehensive treatment strategy that includes dietary changes, physical activity, and behavioral support, reinforcing the notion that medication alone is insufficient for effective obesity management [2].

The guidelines emphasize the importance of patient selection, recommending that healthcare providers assess individual health histories and clinical indications before prescribing GLP-1 medications [4].

WHO's recommendations also highlight the necessity for equitable access to GLP-1 therapies across different income levels, aiming to support the development of sustainable obesity care programs globally [3].

What This Means for Clinical Practice

The new WHO guidelines for GLP-1 therapies represent a significant shift in the management of obesity, emphasizing the need for a multifaceted approach that includes pharmacotherapy, lifestyle modifications, and ongoing support. Clinicians should evaluate patients for GLP-1 therapy based on their BMI and the presence of comorbid conditions, ensuring that treatment is tailored to individual needs. This guideline not only enhances the understanding of obesity as a chronic disease but also promotes the integration of GLP-1 therapies into standard care protocols. As these medications become more widely recognized, the challenge will be to ensure that all patients have access to these effective treatments, particularly in underserved populations. How will healthcare systems adapt to these guidelines to improve patient outcomes?

Clinical Perspective

Workflow: Clinicians should integrate GLP-1 therapies into obesity management protocols, ensuring patient selection aligns with WHO guidelines.

Economics: The guidelines aim to promote equitable access to obesity treatments, potentially reducing long-term healthcare costs associated with obesity-related comorbidities.

Patient Outcomes: By following these guidelines, healthcare providers can improve patient outcomes through tailored obesity management strategies.

Dr. Amit Desai, Endocrinology

WHO Releases 2026 Guidelines for GLP-1 Therapies in Obesity Management

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Langlara: New Biosimilar Insulin for Cost-Effective Diabetes Management

FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Kids Ages 4 and Up

FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

Verified HCP Portal